As expected, U.S. Sen. Richard Burr (R-N.C.) on Tuesday was formally named the highest-ranking Republican member of the Senate Health, Education, Labor, and Pensions (HELP) committee, the Senate committee with jurisdiction over the 340B program.
“As Ranking Member of the
…
A federal district judge in Oakland, Calif., is scheduled to hold a hearing this afternoon on the U.S. Health and Human Services (HHS) Department’s motion to dismiss a lawsuit against it by 340B hospitals over HHS’s enforcement of its 340B
…
U.S. Reps. Peter Welch (D-Vt.) and David McKinley (R-W.Va.) have reintroduced bipartisan legislation in the U.S. House to give 340B rural and free-standing cancer hospitals access to 340B pricing on orphan drugs—which according to a 2019 study are 25
…
A second Republican 340B-related amendment, regarding what covered entities could charge patients for insulin, was offered and then tabled in the U.S. Senate late last week to a budget bill linked to Democrats’ forthcoming COVID-19 relief package.
Sen. Kevin Cramer’s
…
California health centers asked Gov. Gavin Newsom (D) on Friday to delay implementing his controversial transfer of Medicaid drug benefits from managed care to fee for service until January 2022, to let health centers “focus on the needs of their
…Hikma Pharmaceuticals USA, the U.S. division of U.K.-based generic drug manufacturer Hikma Pharmaceuticals plc, is crediting 340B covered entities for overcharges on a long list of NDCs from the fourth quarter of 2017 through the fourth quarter of 2020.
The
…
A Republican amendment offered, then tabled, in the U.S. Senate Feb. 4-5 to a budget bill linked to Democrats’ forthcoming COVID-19 relief package could have led to Senate action related to “improving transparency” in the 340B program “through data reporting.”
…
The bipartisan group of six U.S. House members that got 217 total representatives last fall—173 Democrats and 44 Republicans—to sign a letter opposing efforts to replace up-front 340B drug discounts with back-end rebates began circulating a new 340B sign-on letter
…
Some drug manufacturers have grabbed headlines and precipitated lawsuits for ending 340B pricing on drugs dispensed by contract pharmacies. But behind the scenes, drug companies also are investing in other ways to reduce their exposure to 340B program sales, which
…*Sign up for news summaries and alerts from 340B Report